October 25, 2021
Establishing the Test-Retest Reliability and Minimal Detectable Change of the Multiple Sclerosis Resiliency Scale (MSRS)
Background: The Multiple Sclerosis Resiliency Scale (MSRS) is the first measure designed to assess the factors connected to resilience...
October 25, 2021
Identifying Behavioral Targets to Reduce Missed Multiple Sclerosis-Related Appointments: Potential Implications for Interventions
Background: Missed appointments without cancellation or no shows can cause disruptions in necessary healthcare services, which can be...
Poster-Disease-modifying Therapy
October 25, 2021
Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent
Background: In PREVENT, eculizumab was associated with a significant reduction in relapse risk versus placebo and was well tolerated. In...
Poster-Disease-modifying Therapy
October 25, 2021
Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study
Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...